The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases

Journal of Advanced Pharmaceutical Technology and Research

Volumn 2, Issue 4, 2011, Pages 236-240

  Tyagi, Sandeep ^a   Gupta, Paras ^a   Saini, Arminder ^a   Kaushal, Chaitnya ^a   Sharma, Saurabh ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Diabetes; dyslipidemia; peroxisome proliferator activated receptors

Indexed keywords

CELL NUCLEUS RECEPTOR; GLITAZONE DERIVATIVE; ISOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTINEOPLASTIC ACTIVITY; BRAIN INJURY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INFLAMMATORY DISEASE; LUNG DISEASE; MOLECULAR PATHOLOGY; NEOPLASM; NERVE CELL DIFFERENTIATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PAIN; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 84855209400     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.90879     Document Type: Review

References (42)

1. Michalic L, Wahil W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. Clin Investig J 2006;116:598-606.
2. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB, Costa, KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007;561:194-201. (Pubitemid 46435842)
3. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochem Biophys Acta 2007;1771:915-25. (Pubitemid 47208545)
4. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61. (Pubitemid 38508511)
5. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M."PPAR dual agonists: Are they opening Pandora's Box?" Pharmacol Res 2007:56:91-8. (Pubitemid 47304493)
6. Lemberger T, Braissant O, Aubry C, Keller H, Saladin R, Staels B, et al. PPAR tissue distribution and interactions with other hormone -signalling pathways. Ann NY Acad Sci 1996;804:231-51. (Pubitemid 27056613)
7. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid receptor agonists. Nature 1997;386:407-10. (Pubitemid 27154482)
8. Moreno S, Farioli-Vecchioli S, Cerù MP. Immuno localization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123:131-45. (Pubitemid 37518482)
9. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 2007;1771:1031-45. (Pubitemid 47208548)
10. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80. (Pubitemid 43326861)
11. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008;28:1050-9.
12. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs from orphan receptors to drug discovery. J Med Chem 2000;43:527-50. (Pubitemid 30127149)
13. Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-51. (Pubitemid 40603072)
14. Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007;3:33-9. (Pubitemid 46592792)
15. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol 2008;28:39-46.
16. Bouwens M, Afman LA, Müller M. Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid beta-oxidation: Functional role of peroxisome proliferator activated receptor alpha in human peripheral blood mononuclear cells. Am J Clin Nutr 2007; 86:1515-23. (Pubitemid 350126259)
17. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, WillsonTM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR gamma). J Biol Chem 1995;270:12953-6.
18. Kubota N, Terauchi Y, Kubota, kumagai H, Itoh S, Moroi M, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and independent pathways. J Biol chem 2006;281:8748-55. (Pubitemid 43847980)
19. Ferre P. The biology of peroxisome proliferator-activated receptor. Diabetes 2004;53:S43-50.
20. Barish GD, Narkar VA, Evans RM. PPAR delta: A dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-7. (Pubitemid 43326863)
21. Nagasawa T, Inada Y, Nakano S, Tamura T, Takashashi T, Maruyama K, et al. Effects of bezafibrate, PPAR pan agonist and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine and choline-deficient diet. Eur J Phamacol 2006;536:182-91.
22. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. The PPAR delta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atheroscerosis 2005;181:29-37. (Pubitemid 40804690)
23. Badr. MZ. PPAR research: Successful launching and promising future. PPAR Res 2009;10:11-55.
24. Planavila A, Laguna JC, Vázquez-Carrera M. Nuclear factor kappa B activation leads to down-regulation of fatty acid oxidation during Cardiac hypertrophy. J Biol Chem 2005;280:17464-71. (Pubitemid 41389218)
25. D'Agostino G, LaRana G, Russo R, Sasso O, Iacono A, Esposito E, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferatoractivated receptor-alpha agonist, modulates carrageenan- induced paw edema in mice. J Pharmacol Exp Ther 2007;322:1137-43. (Pubitemid 47295805)
26. DeFilippis D, D'Amico A, Cinelli MP, Esposito G, DiMarzo V, Iuvone T. Adelmidrol, a palmitoylethanolamide analog, reduces chronic inflammation in a carrageenin-granuloma model in rats. J Cell Mol Med 2009;13:1086-95.
27. Majdalawieh A, Ro HS. PPARγ1 and LXRa face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal 2010;8:e004.
28. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, HeymanRA, Briggs M, Deeb S. PPARa and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-48. (Pubitemid 26336216)
29. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE. Cross regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway Of adipogenesis and insulin sensitivity. Mol Cell 1999;3:151-8. (Pubitemid 29292616)
30. Matsusue K, Jefrey M, Peter, frank J. PPAR β/δ potentiates PPARγ- stimulated adipocyte differentiation. FASEB 2004;18:1477-9. (Pubitemid 39561620)
31. Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, et al. New Troglitazone derivatives devoid of PPARa agonist activity display and Increased antiproliferative effect in both hormone dependent and hormone-independent breast cancer cell lines. Breast Cancer Res Treat 2010;124:101-10.
32. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of Peroxisome proliferator-activated receptor gamma agonists. Lancer Oncol 2004;5:419-29. (Pubitemid 38878045)
33. Rubin G, Zhao Y, Kalus A, Simpson E. Peroxisome proliferatoractivated receptor gamma ligands estrogen biosynthesis in human breast adipose tissue; possible implication for the breast cancer therapy. Cancer Res 2000;60:1604-8. (Pubitemid 30183431)
34. Chattopadhyay N, Singh D, Heese O, Godbole MM, Sinohara T, Black PM, et al. Expression of peroxisome proliferator-activated receptors in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 2000;61:67-74. (Pubitemid 30436476)
35. Racke MK, Drew PD. PPARs in Neuroinflammation. PPAR Res 2008:638356.
36. Swerdlow R. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 2007;85:3416-28. (Pubitemid 350058530)
37. Terauchi Y, Kadowaki T. PPAR and diabetes. Nippon Rinsho 2005;63:623-9.
38. LoVerme, J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006;319:1051-61.
39. D'Agostino, G, LaRana G, Russo R, Sasso O, Iacono A, EspositoE, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009;613:54-9.
40. Taylor BK, Kriedt C, Nagalingam S, Dadia N, Badr. M. Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm Res 2005;54:235-42. (Pubitemid 40853838)
41. Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, TaylorBK. Intrathecal rosiglitazone acts at peroxisome proliferatoractivated receptor gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49.
42. Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7